Johnson & Johnson Diabetes Medicine Faces Big Test
Johnson & Johnson (NYSE:JNJ) takes a critical step toward approval of a new diabetes drug Thursday but it must first answer questions about the medicine’s safety. In documents prepared for a panel of US government advisers released Tuesday staff reviewers for the Food and Drug Administration said J&J’s experimental therapy Invokana appears to work but also may have some safety risks that need to be discussed before any approval is granted for the product. Side effects for the drug also known as canagliflozin are being examined by government officials. FDA reviewers appear to be most concerned about cardiovascular risk ...
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here